The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not well tolerated in many elderly patients, hence the unmet medical need for effective therapies with less toxicity and better tolerability. Inhibitors of FMS-like tyrosine kinase 3 (FLT3), JAK2 and histone deace...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Novotny-Diermayr, V, Hart, S, Goh, K C, Cheong, A, Ong, L-C, Hentze, H, Pasha, M K, Jayaraman, R, Ethirajulu, K, Wood, J M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3366067/
https://ncbi.nlm.nih.gov/pubmed/22829971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2012.14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados